The data indicate KAN-101 reduces multiple gluten induced symptoms and celiac-specific composite measures in a Phase 2 trial KAN-101 was safe and tolerated in individuals with celiac disease Celiac ...
L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use ...
Bioengineers have developed a new construction kit for building custom sense-and-respond circuits in human cells. The research could revolutionize therapies for complex conditions like autoimmune ...